Skip to main content
. 2017 Feb 13;7:42503. doi: 10.1038/srep42503

Table 3. GEE analysis results of the 536 chronic hepatitis C patients who underwent anti-hepatitis C virus therapy.

Variants PAI-1 (ng/ml)
95% CI of estimated exp (β) [Estimated exp. (β)] p-values
Sex (female) 0.214~0.848 (0.426) 0.015*
Age 0.939~1.012 (0.975) 0.181
BMI 1.043~1.296 (1.163) 0.007*
Therapy intervention (without) 0.012~0.155 (0.043) <0.001*
Therapy duration 0.841~1.346 (1.064) 0.553
SVR 0.202~1.514 (0.552) 0.249
HCV genotype 0.59~2.354 (1.178) 0.642
HCV RNA (Log10 IU/ml) 0.683~1.281 (0.935) 0.676
HOMA-IR 1.003~1.066 (1.034) 0.003*
ALT (U/L) 0.994~1.004 (0.999) 0.704
APRI 1.038~1.1 (1.069) <0.001*
hsCRP (mg/dL) 0.941~1.279 (1.097) 0.235
WBC count (103/μL) 0.982~1.253 (1.235) 0.07
Platelets count (103/μL) 1.018~1.033 (1.026) <0.001*
Hepatic steatosis (yes) 0.569~2.014 (1.07) 0.833
Liver cirrhosis (yes) 0.596~3.476 (1.495) 0.391
TC (mg/dL) 0.972~0.998 (0.985) 0.023*
TGs (mg/dL) 1.002~1.006 (1.004) 0.001*
PAI-1 (ng/ml) NA NA
BNP (Log10 pg/mL) 0.189~2.627 (0.704) 0.602
Homocysteine (μmol/L) 0.234~3.86 (1.234) 0.885
eGFR 1.001~1.045 (1.023) 0.042*
PAI-1-rs1799889 (4 G/4 G genotype) 1.69~4.09 (2.63) <0.001*
IFNL3-rs12979860 (CC genotype) 1.18~4.18 (2.22) 0.013*

Estimates of exp. (β), 95% confidence interval (CI) of exp. (β) and p-values for the variants that predicted PAI-1 longitudinally. GEE: generalized estimating equation; CI: confidence interval; OR: odds ratio; *p < 0.05; NA, not accessible; SVR: sustained virological response; BMI: body mass index; Log: logarithmic; HOMA-IR: homeostasis model assessment-estimated insulin resistance; ALT: alanine aminotransferase; APRI: aspartate aminotransferase to platelet ratio index; hsCRP: high sensitivity C-reactive protein; WBC: white blood cells; TC: total cholesterol; TGs: triglycerides; PAI-1: plasminogen activator inhibitor-1; BNP: brain natriuretic peptide; eGFR: estimated glomerular filtration rate; IFNL3: interferon-λ3.